The company’s autumn tour kicks off at the DGAI meeting in Kassel, Germany, from September 16-18, followed by the Kongress für Nephrologie in Leipzig in early October. At the ESICM Lives event in Lisbon, SphingoTec will co-host a scientific symposium on sepsis diagnostics alongside partner Boditech, while simultaneously unveiling multicenter study data on its penKid biomarker.
Attention shifts to the United States on October 22 for the ASN Kidney Week in Denver, where the company will present an abstract detailing how Proenkephalin predicts severe acute kidney injury in high-risk patients. The final stretch of the year includes a focus on international networking at Medica in Düsseldorf and a concluding appearance at the DIVI congress in Hamburg this December.
CEO Deborah Bergmann emphasized that these engagements are designed to turn research into tangible clinical outcomes. By maintaining a presence at these multidisciplinary forums, the firm seeks to accelerate the adoption of its proprietary portfolio, which includes the penKid and bio-ADM biomarkers, across global medical platforms.
Comments (0)
No comments yet. Be the first!